Monthly subscription value of $1.83 million as of October 31, 2026, approximately $22.0 million on an annualized
Active subscriptions up 92%: 12,050 active U.S. subscriptions as of October 28, 2026, up from 6,287 on October 14,
revenue: approximately $15 million expected, based on the Company's current growth trajectory● Q4 2026 gross profit: approximately $10.5 million expected, at an approximately 70% gross margin● Subscription revenue: approximately $11.
● 6,287 active U.S. subscriptions as of October 14, 2026, the vast majority added since mid-September as the Company
* Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreements * Gross margins of over 90% \- among the highest-margin revenue streams in the Company, with raw materials largely supplied by clients * Record production pipeline of more than 32.7 million units, up approximately sixfold since mid-2024 and close to threefold since the start of this year, with
7 million contracted units added in under two weeks \- Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today * Secured orders for 1.
* Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock * Positions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets. * CCX0722 is an ingestible, hydrogel-based medical device in development for weight management, using a mechanical mechanism with no systemic absorption * Intellectual property owned outright, with pat
* 500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories * Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolio * Cumulative contract manufacturing orderbook increases to more than 27.
Cosmos Health (COSM) said Friday its unit Cana Laboratories entered a new five-year contract manufac
2 million in adjusted EBITDA and $31 million in net incomeCHICAGO, IL / ACCESS Newswire / September 9, 2026 / ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has received its first orders for its veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet.C-ScrubVet Wash 4% CHDG is a veterinary antimicrobial cleanser containing 4% chlorhexidine digluconate, effective against bacteria
A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) →...
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
This is the newest page. Registered accounts read further back.